Anaplastic Oligoastrocytoma - Pipeline Review, H1 2018

  • ID: 4540585
  • Drug Pipelines
  • 72 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • AbbVie Inc
  • Astellas Pharma Inc
  • Boehringer Ingelheim GmbH
  • Novartis AG
  • Pfizer Inc
  • MORE
Anaplastic Oligoastrocytoma - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Anaplastic Oligoastrocytoma - Pipeline Review, H1 2018, provides an overview of the Anaplastic Oligoastrocytoma (Oncology) pipeline landscape.

Anaplastic oligoastrocytoma is a brain tumor that forms when two types of cells in the brain, called oligodendrocytes and astrocytes, rapidly increase in number to form a mass. These brain cells are known as glial cells, which normally protect and support nerve cells in the brain. Symptoms include seizures, headaches, and personality changes. Other symptoms vary by location and size of the tumor. Treatment includes chemotherapy and surgery.

Report Highlights:

This latest pipeline guide Anaplastic Oligoastrocytoma - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Anaplastic Oligoastrocytoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Anaplastic Oligoastrocytoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Anaplastic Oligoastrocytoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Phase I stages are 4 and 3 respectively.

Anaplastic Oligoastrocytoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Anaplastic Oligoastrocytoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Anaplastic Oligoastrocytoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Anaplastic Oligoastrocytoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Anaplastic Oligoastrocytoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Anaplastic Oligoastrocytoma (Oncology)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Anaplastic Oligoastrocytoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Anaplastic Oligoastrocytoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AbbVie Inc
  • Astellas Pharma Inc
  • Boehringer Ingelheim GmbH
  • Novartis AG
  • Pfizer Inc
  • MORE
Introduction

Report Coverage

Anaplastic Oligoastrocytoma - Overview

Anaplastic Oligoastrocytoma - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Anaplastic Oligoastrocytoma - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Anaplastic Oligoastrocytoma - Companies Involved in Therapeutics Development

AbbVie Inc

Astellas Pharma Inc

Boehringer Ingelheim GmbH

Novartis AG

Pfizer Inc

Anaplastic Oligoastrocytoma - Drug Profiles

afatinib dimaleate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bendamustine hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

depatuxizumab mafodotin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

flucytosine + TBio-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

irinotecan + TBio-02 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nilotinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

palbociclib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Anaplastic Oligoastrocytoma - Dormant Projects

Anaplastic Oligoastrocytoma - Discontinued Products

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Anaplastic Oligoastrocytoma, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Anaplastic Oligoastrocytoma - Pipeline by AbbVie Inc, H1 2018

Anaplastic Oligoastrocytoma - Pipeline by Astellas Pharma Inc, H1 2018

Anaplastic Oligoastrocytoma - Pipeline by Boehringer Ingelheim GmbH, H1 2018

Anaplastic Oligoastrocytoma - Pipeline by Novartis AG, H1 2018

Anaplastic Oligoastrocytoma - Pipeline by Pfizer Inc, H1 2018

Anaplastic Oligoastrocytoma - Dormant Projects, H1 2018

Anaplastic Oligoastrocytoma - Discontinued Products, H1 2018

List of Figures

Number of Products under Development for Anaplastic Oligoastrocytoma, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Top 10 Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • AbbVie Inc
  • Astellas Pharma Inc
  • Boehringer Ingelheim GmbH
  • Novartis AG
  • Pfizer Inc
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll